Revolutionizing Biologics Manufacturing: The Bioprocessing Summit Offers Dedicated Cell and Gene Therapy Streams

BOSTON--(BUSINESS WIRE)-- With cell and gene therapies revolutionizing cancer treatment, curing major diseases with a single administration, and commanding blockbuster prices, biologics manufacturers are clamoring to move the “next big drug” into the marketplace.

To help biomanufacturers meet patient demand, while addressing quality, safety, and cost-efficiency challenges, The Bioprocessing Summit from Cambridge Healthtech Institute will feature 60+ presentations across two dedicated week-long conference tracks on Cell Therapy Manufacturing and Gene Therapy Manufacturing. Taking place August 12-16, 2019 at the Seaport World Trade Center, Boston, this premier global conference will bring together 1,500 scientists, engineers, and leaders from biotechnology and pharmaceutical companies, academia, and government.

“The clinical data supporting cell and gene therapies is outstanding. However, robust analytical and manufacturing strategies will determine the long-term success of this industry and supply of such cutting-edge therapies to patients. The Cell and Gene Therapy CMC and Manufacturing tracks at The Bioprocessing Summit will give scientists access to new analytical and manufacturing data, technologies, and contacts to capitalize on a new era,” said Dan Barry, Senior Conference Director for these tracks at The Bioprocessing Summit.

The Cell and Gene Therapy CMC and Manufacturing streams will be part of 16 separate meetings and more than 200 presentations at the event.

Cell Therapy CMC and Manufacturing sessions will explore regulatory and CMC strategies, product and process characterization, automation, and autologous and allogeneic manufacturing for CAR Ts, and next-generation therapies.

Gene Therapy CMC and Manufacturing sessions will focus on viral vector-based gene therapies. Topics will include impurity analysis, potency assay development, process development, scale-up, clinical and commercial manufacturing, purification, and formulation.

The Bioprocessing Summit will also include new opportunities for one-on-one networking, an Exhibit Hall featuring 110-plus cutting-edge innovators, poster sessions, and more. See

About Cambridge Healthtech Institute
Cambridge Healthtech Institute (CHI), a division of Cambridge Innovation Institute, is the preeminent life science network for leading researchers and business experts from top pharmaceutical, biotech, CROs, academia, and niche service providers. CHI is renowned for its vast conference portfolio held worldwide including PepTalk, Molecular Medicine Tri-Conference, SCOPE Summit, Bio-IT World Conference & Expo, PEGS Summit, Drug Discovery Chemistry, Biomarker World Congress, World Preclinical Congress, The Bioprocessing Summit, Next Generation Dx Summit, Immuno-Oncology Summit, and Discovery on Target. CHI's portfolio of products include Cambridge Healthtech Institute Conferences, Barnett International, Insight Pharma Reports, Bio-IT WorldClinical Research News, and Diagnostics World.



Dawn Ringel



Source: Cambridge Healthtech Institute

Back to news